deltatrials
Terminated PHASE2 INTERVENTIONAL 2-arm NCT02980705

Efficacy and Safety Study of SUNPG1622

A Randomized, Double-blind, Placebo-controlled Phase 2a Study to Evaluate the Efficacy and Safety of Tildrakizumab in Subjects With Active Ankylosing Spondylitis or Non-radiographic Axial Spondyloarthritis

Sponsor: Sun Pharmaceutical Industries Limited

Conditions Active Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis
Interventions Placebo dose SUNPG1622 I dose
Updated 18 times since 2017 Last updated: Oct 29, 2021 Started: Nov 6, 2017 Primary completion: Feb 21, 2019 Completion: Sep 3, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Study terminated-Sponsor's decision

Other terminated trials from Sun Pharmaceutical Industries Limited

More terminations from Sun Pharmaceutical Industries Limited

A PHASE2 clinical study on Active Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis, this trial is terminated or withdrawn. The trial is conducted by Sun Pharmaceutical Industries Limited and has accumulated 18 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jul 2017 · 5 months · monthly snapshot~Jul 2017 – ~Mar 2018 · 8 months · monthly snapshot~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Nov 2018 · 5 months · monthly snapshot~Nov 2018 – ~Dec 2018 · 30 days · monthly snapshot~Dec 2018 – ~Mar 2019 · 3 months · monthly snapshot~Mar 2019 – ~May 2019 · 2 months · monthly snapshot~May 2019 – ~Jun 2019 · 31 days · monthly snapshot~Jun 2019 – ~Jul 2019 · 30 days · monthly snapshot~Jul 2019 – ~Aug 2020 · 13 months · monthly snapshot~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Dec 2021 · 9 months · monthly snapshot~Dec 2021 – ~Jul 2024 · 31 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 12 months · monthly snapshot

Change History

18 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  4. Dec 2021 — Jul 2024 [monthly]

    Terminated PHASE2

  5. Mar 2021 — Dec 2021 [monthly]

    Terminated PHASE2

▶ Show 13 earlier versions

  1. Jan 2021 — Mar 2021 [monthly]

    Terminated PHASE2

  2. Aug 2020 — Jan 2021 [monthly]

    Terminated PHASE2

  3. Jul 2019 — Aug 2020 [monthly]

    Terminated PHASE2

    Status: Active Not Recruiting → Terminated

  4. Jun 2019 — Jul 2019 [monthly]

    Active Not Recruiting PHASE2

  5. May 2019 — Jun 2019 [monthly]

    Active Not Recruiting PHASE2

  6. Mar 2019 — May 2019 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  7. Dec 2018 — Mar 2019 [monthly]

    Recruiting PHASE2

  8. Nov 2018 — Dec 2018 [monthly]

    Recruiting PHASE2

  9. Jun 2018 — Nov 2018 [monthly]

    Recruiting PHASE2

  10. Mar 2018 — Jun 2018 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  11. Jul 2017 — Mar 2018 [monthly]

    Not Yet Recruiting PHASE2

  12. Feb 2017 — Jul 2017 [monthly]

    Not Yet Recruiting PHASE2

  13. Jan 2017 — Feb 2017 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Sun Pharmaceutical Industries Limited
Data source: Sun Pharmaceutical Industries Limited

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations